-
Mashup Score: 3What Is the Role of Splenic Irradiation Before HSCT in Patients With MF? | Blood Cancers Today - 20 hour(s) ago
Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with MF.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Subcutaneous Sotatercept Is Safe, Effective in Patients With PMF, Anemia | Blood Cancers Today - 2 day(s) ago
Sotatercept monotherapy, and in combination with ruxolitinib, was found to be a safe and effective treatment for primary myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Sotatercept alone, and combined with ruxolitinib, is a safe and effective treatment for patients with primary #myelofibrosis with anemia. Read more about the phase II trial, led by @bose_prithviraj, of @MDAndersonNews, and published in @Haematologica. 📰 https://t.co/HPfprxRT7D https://t.co/1f6kXGe7km
-
-
Mashup Score: 2Key Findings from COMFORT I and II Trials - 3 day(s) ago
Dr. Bose discusses the key findings from the COMFORT I and II trials and how the overall survival data has impacted the way he manages patients with myelofibrosis, along with the factors that most inform his treatment decisions.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Initial Impressions and Comparison to Typical Cases - 4 day(s) ago
Dr. Bose discusses his initial impressions of the case and how it compares to typical myelofibrosis cases seen in his practice.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0
Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 27
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization To create an adaptation, translation, or derivative of the original work, for commercial e-pr ints and printed articles further permission is required. For information contact: marketing@haematologica.org
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Combination Therapy Demonstrates ‘Potential Disease-Modifying Activity’ in Myelofibrosis | Blood Cancers Today - 25 day(s) ago
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with JAKi-naïve myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1What Is the Impact of GVHD on Myelofibrosis Relapse After HSCT? | Blood Cancers Today - 1 month(s) ago
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1What Is the Impact of GVHD on Myelofibrosis Relapse After HSCT? | Blood Cancers Today - 2 month(s) ago
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with #myelofibrosis. Read more about the study, led by @NicoGagelmann, of @UKEHamburg, and published in @AjHematology. 📰 https://t.co/miBqTylIH7 https://t.co/GEd0iiG0mf